

I'm not a robot























[illegible]

neutrophil gelatinase-associated lipocalin among children with normalalbuminuria. Iran J. Kidney Dis. 2015;9:126-131. [PubMed] [Google Scholar] 68.Schmidt-Ott K.M., Mori K., Li J.Y., Kalandazade A., Cohen D.J., Devarajan P., Barasch J. Dual action of neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 2007;18:407-413. doi: 10.1681/ASN.20060882. [DOI] [PubMed] [Google Scholar] 69.El-Ej, J., Mammo T., Goss P., Mori K., Kariwala S., Barasch J., Sukhatme V.P. Lipocalin-2 diminishes invasiveness and metastasis of Ras-transformed cells. J. Biol. Chem. 2005;280:13641-13647. doi: 10.1074/jbc.M413047200. [DOI] [PubMed] [Google Scholar] 70. Fernández C.A., Yan L., Louis G., Yang J., Kutok J.L., Moses M.A. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin. Cancer Res. 2005;11:5390-5395. doi: 10.1158/1078-0432.CCR-04-2391. [DOI] [PubMed] [Google Scholar] 71.Leng X., Ding T., Lin H., Wang Y., Hu L., Ju J., Feig B., Zhang W., Pustai L., Symmans W.F., et al. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 2009;69:8579-8584. doi: 10.1158/0008-5472.CAN-09-1934. [DOI] [PubMed] [Google Scholar] 72.Yang J., Bielenberg D.P., Rodig S.J., Doiron R., Clifton M.C., Kung A.L., Strong R.K., Zurakowski D., Moses M.A. Lipocalin 2 promotes breast cancer progression. Proc. Natl. Acad. Sci. USA. 2009;106:3913-3918. doi: 10.1073/pnas.0810611706. [DOI] [PMC free article] [PubMed] [Google Scholar] 73.Leng X., Wu Y., Airlinghaus R.B. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J. Cell. Physiol. 2011;126:309-314. doi: 10.1002/jcp.22403. [DOI] [PubMed] [Google Scholar] 74.Iannetti A., Pacifico F., Acquaviva R., Lavorgna A., Crescenzi E., Vascotto C., Tell G., Salzano A.M., Scalonì A., Vuttariello E., et al. The neutrophil gelatinase-associated lipocalin (NGAL) is a survival factor for thyroid neoplastic cells. Proc. Natl. Acad. Sci. USA. 2008;105:14058-14063. doi: 10.1073/pnas.0710846105. [DOI] [PMC free article] [PubMed] [Google Scholar] 75.Volpe V., Raia Z., Sanguigno L., Somma D., Mastrovito P., Moscato F., Mellone S., Leonardi A., Pacifico F. NGAL controls the metastatic potential of anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2013;98:228-235. doi: 10.1210/jc.2012-2528. [DOI] [PubMed] [Google Scholar] 76.Kubben F.J., Sier G.F., Hawkins L.J., Teschesche H., van Duijn W., Zuidwijk K., van der Reijden J.J., Hanemaaijer R., Griffioen G., Lamers C.B., et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur. J. Cancer. 2007;43:1869-1876. doi: 10.1016/j.ejca.2007.05.013. [DOI] [PubMed] [Google Scholar] 77.Koh S.A., Lee K.H. HGF mediated upregulation of lipocalin 2 regulates MMP9 through nuclear factor-κB activation. Oncol. Rep. 2015;34:2179-2187. doi: 10.3892/ora.2015.4189. [DOI] [PubMed] [Google Scholar] 78.Du Z., Liu B.L., Xie Y.M., Zhan Y.L., Liao L.D., Zhou F., Xie J.J., Zong F.M., Xu X.E., Fang W.K., et al. Lipocalin 2 promotes the migration and invasion of esophageal squamous cell carcinoma cells through a novel positive feedback loop. Biochim. Biophys. Acta. 2015;1853:2240-2250. doi: 10.1016/j.bbmr.2015.07.007. [DOI] [PubMed] [Google Scholar] 79.Zhang H., Xu L., Xiao D., Xie J., Zeng H., Wang Z., Xiang X., Niu Y., Shen Z., Shen J., et al. Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: Significant correlation with cell differentiation and tumour invasion. J. Clin. Pathol. 2007;60:555-561. doi: 10.1136/jcp.2006.039297. [DOI] [PMC free article] [PubMed] [Google Scholar] 80.Ding G., Fang J., Tong S., Qu L., Jiang H., Ding Q., Liu J. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer. Prostate. 2015;75:957-968. doi: 10.1002/pros.22978. [DOI] [PubMed] [Google Scholar] 81.Tung M.C., Hsieh S.C., Yang S.F., Cheng C.W., Tsai R.T., Wang S.C., Huang M.H., Hsieh Y.H. Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells. Prostate. 2013;73:1281-1290. doi: 10.1002/pros.22670. [DOI] [PubMed] [Google Scholar] 82.Lippi G., Meschi T., Nounvenne A., Mattiuzzi C., Borghi L. Neutrophil gelatinase-associated lipocalin (NGAL) is a survival factor for thyroid neoplastic cells. Proc. Natl. Acad. Sci. USA. 2008;105:14058-14063. doi: 10.1073/pnas.0710846105. [DOI] [PMC free article] [PubMed] [Google Scholar] 83.Chakraborty S., Kaur S., Guha S., Batra S.K. The multifaceted roles of neutrophil gelatinase-associated lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys. Acta. 2012;1826:129-169. doi: 10.1016/j.bbcan.2012.03.008. [DOI] [PMC free article] [PubMed] [Google Scholar] 84.Rodvold J.J., Mahadevan N.R., Zanetti M. Lipocalin 2 in cancer: When good immunity goes bad. Cancer Lett. 2012;316:132-138. doi: 10.1016/j.canlet.2011.11.002. [DOI] [PubMed] [Google Scholar] 85.Candido S., Maestro R., Polesel J., Catania A., Maira F., Signorelli S., McCubrey J.A., Libra M. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. J. Cell. Physiol. 2014;157:157-164. doi: 10.1002/jcp.23748. [DOI] [PubMed] [Google Scholar] 86.Mishra R.K., Prada A., Mitsnes M., Zahedi K., Yang J., Barasch J., Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 2003;14:2534-2543. doi: 10.1097/01.ASN.0000088027.54400.06. [DOI] [PubMed] [Google Scholar] 87.Mishra J., Dent C., Tarabishi R., Mitsnes M.M., Ma Q., Kelly C., Ruff S.M., Zahedi K., Shao M., Bean J., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231-1238. doi: 10.1016/S0140-6736(05)74811-X. [DOI] [PubMed] [Google Scholar] 88.Koyner J.L., Vaidya V.S., Bennett M.R., Ma Q., Worcester E., Akhter S.A., Raman J., Jeevanandam V., O'Connor M.F., Devarajan P., et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin. J. Am. Soc. Nephrol. 2010;5:2154-2165. doi: 10.2215/CJN.00740110. [DOI] [PMC free article] [PubMed] [Google Scholar] 89.De Geus H.R., Bakker J., Lesaffre E., Le Noble J.L. Neutrophil gelatinase-associated lipocalin at ICU admission predicts for acute kidney injury in adult patients. Am. J. Respir. Crit. Care Med. 2011;183:907-914. doi: 10.1164/rccm.200908-1214OC. [DOI] [PubMed] [Google Scholar] 90.Devarajan P. Review: Neutrophil gelatinase-associated lipocalin: A troponin-like biomarker for human acute kidney injury. Nephrology. 2010;15:419-428. doi: 10.1111/1440-1797.2010.01317.x. [DOI] [PubMed] [Google Scholar] 91.Ahn J.Y., Lee M.J., Seo J.S., Choi D., Park J.B. Plasma neutrophil gelatinase-associated lipocalin as a predictive biomarker for the detection of acute kidney injury in adult poisoning. Clin. Toxicol. 2016;54:127-133. doi: 10.3109/15563605.2015.1118487. [DOI] [PubMed] [Google Scholar] 92.Luo Q.H., Chen M.L., Sun F.J., Chen Z.L., Li M.Y., Zeng W., Gong L., Cheng A.C., Peng X., Fang J., et al. KIM-1 and NGAL as biomarkers of nephrotoxicity induced by gentamicin in rats. Mol. Cell. Biochem. 2014;397:53-60. doi: 10.1007/s11010-014-2171-7. [DOI] [PubMed] [Google Scholar] 93.Vannemsenhove J., Vanholder R., Nagler E., Van Biesen W. Urinary and serum biomarkers for the diagnosis of acute kidney injury: An in-depth review of the literature. Nephrol. Dial. Transplant. 2013;28:254-273. doi: 10.1093/ndt/gfs380. [DOI] [PubMed] [Google Scholar] 94.Dragan D., Hase M. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery - A prospective cohort study. Crit. Care Med. 2009;37:553-560. doi: 10.1097/CCM.0b013e318195846e. [DOI] [PubMed] [Google Scholar] 94a.Makris K., Markou N., Evodia E., Dimopoulou E., Drakopoulos E., Ntetsika K., Rizos D., Baltopoulos G., Haliaouas A. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin. Chem. Lab. Med. 2009;47:79-82. doi: 10.1515/CCCLM.2009.004. [DOI] [PubMed] [Google Scholar] 95.Ozkan S., Durukan P., Kavali C., Duman A., Sayhan M.A., Sait O., Ipekci A. Importance of neutrophil gelatinase-associated lipocalin in differential diagnosis of acute and chronic renal failure. Iran Red. Crescent. Med. J. 2014;16:e14133. doi: 10.5812/ircmj.14133. [DOI] [PMC free article] [PubMed] [Google Scholar] 96.Corbacioglu S.K., Cevik Y., Akinci E., Uzunosmanoglu H., Dagar S., Safak T., Oncul V., Guvendı M. Value of plasma neutrophil gelatinase-associated lipocalin (NGAL) in distinguishing between acute kidney injury (AKI) and chronic kidney disease (CKD) Turk. J. Emerg. Med. 2017;17:85-88. doi: 10.1016/j.tjem.2017.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar] 97.Gharisvandı F., Kazerooni F., Ghanei E., Rahimpour A., Nasiri M. Comparative assessment of neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C as early biomarkers for early detection of renal failure in patients with hypertension. Iran Biomed. J. 2015;19:76-81. doi: 10.6091/ibj.1380.2015. [DOI] [PMC free article] [PubMed] [Google Scholar] 98.Bolognino D., Donato V., Coppolino G., Campo S., Buemi A., Lacquaniti A., Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am. J. Kidney Dis. 2008;52:595-605. doi: 10.1053/ajkd.2008.01.020. [DOI] [PubMed] [Google Scholar] 99.Grigoryev D.N., Liu M., Hassoun H.T., Cheadle C., Barnes K.C., Rabb H. The local and systemic inflammatory transcriptome after acute kidney injury. J. Am. Soc. Nephrol. 2008;19:547-558. doi: 10.1681/ASN.2007040469. [DOI] [PMC free article] [PubMed] [Google Scholar] 100.Devarajan P. The promise of biomarkers for personalized renal cancer care. Kidney Int. 2010;77:755-757. doi: 10.1038/kid.2010.26. [DOI] [PubMed] [Google Scholar] 101.Hase-Rietz A., Bellomo R., Devarajan P., Story D., Matalanis G., Dragan D., Hase M. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery - A prospective cohort study. Crit. Care Med. 2009;37:553-560. doi: 10.1097/CCM.0b013e318195846e. [DOI] [PubMed] [Google Scholar] 104.Makris K., Markou N., Evodia E., Dimopoulou E., Drakopoulos E., Ntetsika K., Rizos D., Baltopoulos G., Haliaouas A. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin. Chem. Lab. Med. 2009;47:79-82. doi: 10.1515/CCCLM.2009.004. [DOI] [PubMed] [Google Scholar] 105.Ozkan S., Durukan P., Kavali C., Duman A., Sayhan M.A., Sait O., Ipekci A. Importance of neutrophil gelatinase-associated lipocalin in differential diagnosis of acute and chronic renal failure. Iran Red. Crescent. Med. J. 2014;16:e14133. doi: 10.5812/ircmj.14133. [DOI] [PMC free article] [PubMed] [Google Scholar] 106.Corbacioglu S.K., Cevik Y., Akinci E., Uzunosmanoglu H., Dagar S., Safak T., Oncul V., Guvendı M. Value of plasma neutrophil gelatinase-associated lipocalin (NGAL) in distinguishing between acute kidney injury (AKI) and chronic kidney disease (CKD) Turk. J. Emerg. Med. 2017;17:85-88. doi: 10.1016/j.tjem.2017.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar] 107.Gharisvandı F., Kazerooni F., Ghanei E., Rahimpour A., Nasiri M. Comparative assessment of neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C as early biomarkers for early detection of renal failure in patients with hypertension. Iran Biomed. J. 2015;19:76-81. doi: 10.6091/ibj.1380.2015. [DOI] [PMC free article] [PubMed] [Google Scholar] 108.Bolognino D., Donato V., Coppolino G., Campo S., Buemi A., Lacquaniti A., Coppolino G., Donato V., Campo S., Fazio M.R., Nicocia G., Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009;4:437-444. doi: 10.2215/CJN.03530708. [DOI] [PMC free article] [PubMed] [Google Scholar] 109.Glasson J., Li G.H., Chen Y. Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non-acute kidney injury (AKI) diseases. Inflamm. Allergy Drug Targets. 2011;10:272-282. doi: 10.1714/187152811796117753. [DOI] [PubMed] [Google Scholar] 110.Malyszko J., Bachorzewska-Gajewska H., Sitniewska E., Malyszko J.S., Dobrzycki B., Dubrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in non-diabetic patients with stage 2-4 chronic kidney disease. PLoS ONE. 2012;7:1167334. doi: 10.1371/journal.pone.0167334. [DOI] [PMC free article] [PubMed] [Google Scholar] 113.Smith E.R., Lee D., Cai M.M., Tomlinson L.A., Ford M.L., McMahon L.P., Gwiner W., Scheffner I., Haller H.C., Schiffer M. Urinary NGAL Ratio Is Not a Sensitive Biomarker for Monitoring Acute Tubular Injury in Kidney Transplant Patients: NGAL and AT1 in Renal Transplant Patients. J. Transplant. 2012;2012:563404. doi: 10.1155/2012/563404. [DOI] [PMC free article] [PubMed] [Google Scholar] 112.Zhou L.T., Li V.L., Pan M.M., Cao Y.H., Liu H., Feng Y., Ni H.F., Liu B.C. Are Urinary Tubular Injury Markers Useful in Chronic Kidney Disease? A Systematic Review and Meta-Analysis. PLoS ONE. 2011;6:167334. doi: 10.1371/journal.pone.0167334. [DOI] [PMC free article] [PubMed] [Google Scholar] 113.Smith E.R., Lee D., Cai M.M., Tomlinson L.A., Ford M.L., McMahon L.P., Gwiner W., Scheffner I., Haller H.C., Schiffer M. Urinary NGAL Ratio Is Not a Sensitive Biomarker for Monitoring Acute Tubular Injury in Kidney Transplant Patients: NGAL and AT1 in Renal Transplant Patients. J. Transplant. 2012;2012:563404. doi: 10.1155/2012/563404. [DOI] [PMC free article] [PubMed] [Google Scholar] 114.Cai M.M., Tomlinson L.A., Ford M.L., McMahon L.P., Gwiner W., Scheffner I., Haller H.C., Schiffer M. Urinary NGAL Ratio Is Not a Sensitive Biomarker for Monitoring Acute Tubular Injury in Kidney Transplant Patients: NGAL and AT1 in Renal Transplant Patients. J. Transplant. 2012;2012:563404. doi: 10.1155/2012/563404. [DOI] [PMC free article] [PubMed] [Google Scholar] 115.Kaufel J., Haesler M., Passfall J., Haesler M., Laschinski P., Buhl M., Bauer F., Rohm B., Babel N., Westhoff T.H. Urinary calprotectin, NGAL, and KIM-1 in the differentiation of primarily inflammatory vs. non-inflammatory stable chronic kidney diseases. Ren. Fail. 2021;43:625-628. doi: 10.1080/08850666.2021.1885442. [DOI] [PMC free article] [PubMed] [Google Scholar] 116.Ntriniat T., Papastoriou M., Balta L., Kalavrizioti D., Vamvakas S., Papachristou E., Goumenos D.S. Biomarkers in Progressive Chronic Kidney Disease. Still a Long Way to Go. Priloz. 2019;40:27-39. doi: 10.2478/priloz.2019.020-0002. [DOI] [PubMed] [Google Scholar] 117.Viau A., El Karoui K., Laouari D., Burtin M., Nguyen C., Mori K., Pillebout E., Berger T., Mak T.W., Knebelmann B., Balta L., Lacquaniti A., Parvez P. Early Urinary Biomarkers in Pediatric Autosomal Dominant Polycystic Kidney Disease Progression in mice and humans. J. Clin. Invest. 2010;120:4065-4076. doi: 10.1172/JCI42404. [DOI] [PMC free article] [PubMed] [Google Scholar] 118.Xiang D., Wang X., Li P., Yang Q., Zhang Q., Chi X., Jing Y., Duan X., Wei Q., Wang J., et al. Increased NGAL levels in human patients with iron store in chronic kidney disease with anemia. Clin. Exp. Nephrol. 2018;18:563-568. doi: 10.1007/s12248-018-0507-4. [DOI] [PubMed] [Google Scholar] 119.Kim J.Y., Kim J.H., Lee D.W., Lee S.B., Rhee H., Song S.H., Seong E.Y., Kwak I.S. Plasma neutrophil gelatinase-associated lipocalin as a biomarker for iron status in anemic patients with pre-dialysis chronic kidney disease. Clin. Exp. Nephrol. 2018;22:28-34. doi: 10.1007/s10157-017-1409-6. [DOI] [PubMed] [Google Scholar] 120.Bolognino D., Coppolino G., Romeo A., Lacquaniti A., Nicocia G., Lombardi L., Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) reflects iron status in haemodialysis patients. Nephrol. Dial. Transplant. 2009;24:3398-3403. doi: 10.1093/ndt/gfp310. [DOI] [PubMed] [Google Scholar] 121.Tomasz G., Ewa W., Jolanta M. Biomarkers of iron metabolism in chronic kidney disease. Int. Urol. Nephrol. 2021;53:935-944. doi: 10.1007/s11255-020-02663-z. [DOI] [PMC free article] [PubMed] [Google Scholar] 122.Batchelor E.K., Kapitapous P., Pergola P.E., Koveshy C.P., Jala D.I. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J. Am. Soc. Nephrol. 2020;31:456-468. doi: 10.1681/ASN.2019020213. [DOI] [PMC free article] [PubMed] [Google Scholar] 123.Seibert F.S., Sitz M., Passfall J., Haesler M., Laschinski P., Buhl M., Bauer F., Rohm B., Babel N., Westhoff T.H. Urinary calprotectin, NGAL, and KIM-1 in the differentiation of primarily inflammatory vs. non-inflammatory stable chronic kidney diseases. Ren. Fail. 2021;43:625-628. doi: 10.1080/08850666.2021.1885442. [DOI] [PMC free article] [PubMed] [Google Scholar] 124.Ding H., He Y., Li J., Xiang L., Lu R., Gao W. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin. Immunol. 2007;123:227-234. doi: 10.1016/j.clim.2007.01.010. [DOI] [PubMed] [Google Scholar] 125.Rhee H., Shin N., Shin M.J., Yang B.Y., Kim I.Y., Song S.H., Lee D.W., Lee S.B., Kwak I.S., Seong E.Y. High serum and urinary neutrophil gelatinase-associated lipocalin levels are independent predictors of renal progression in patients with immunoglobulin A nephropathy. Korean J. Nephrol. 2010;30:354-354. [DOI] [PMC free article] [PubMed] [Google Scholar] 126.Fang G., Chen N.Y., Chen Y.B., Chang Y.B., Seung J.H., Sun F. Urinary neutrophil gelatinase-associated lipocalin for diagnosis and estimating activity in lupus nephritis: A meta-analysis. Lupus. 2015;24:1529-1539. doi: 10.1177/0961203115600244. [DOI] [PubMed] [Google Scholar] 127.Palazzo L., Lindblom J., Mohan C., Parodis I. Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: Current insights. Curr. Opin. Rheumatol. 2022;34:139-149. doi: 10.1097/BOR.0000000000000862. [DOI] [PubMed] [Google Scholar] 129.Rubinstein T., Pitashny M., Putterman C. The novel role of neutrophil gelatinase-B associated lipocalin (Lipocalin-2) as a biomarker for lupus nephritis. Autoimmun. Rev. 2008;7:229-234. doi: 10.1016/j.autrev.2007.11.013. [DOI] [PubMed] [Google Scholar] 130.Bolognino D., Coppolino G., Campo S., Aloisi C., Nicocia G., Frisina N., Buemi M. Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am. J. Nephrol. 2007;27:373-378. doi: 10.1159/000103912. [DOI] [PubMed] [Google Scholar] 131.Vareesangthip K., Vareesangthip K., Limwongse C., Reesukulnaw K. Role of Urinary Neutrophil Gelatinase-Associated Lipocalin for Predicting the Severity of Renal Functions in Patients with Autosomal-Dominant Polycystic Kidney Disease. Transplant. Proc. 2017;49:950-954. doi: 10.1016/j.transproc.2017.03.061. [DOI] [PubMed] [Google Scholar] 132.Meijer E., Boertien W.E., Nauta F.L., Bakker S.J., van Oeveren W., Rook M., van der Jagt E.J., van Goor H., Peters D.J., Navis G., et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: A cross-sectional analysis. Am. J. Kidney Dis. 2010;56:883-895. doi: 10.1053/ajkd.2010.06.023. [DOI] [PubMed] [Google Scholar] 133.Tsingos M., Merlini L., Solca M., Goischke A., Wilhelm-Bals A., Parvez P. Early Urinary Biomarkers in Pediatric Autosomal Dominant Polycystic Kidney Disease (ADPKD): No Evidence in the Interest of Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) From. Pediatr. Transplant. 2019;23:19-28. doi: 10.3399/ped.2019.00088. [DOI] [PMC free article] [PubMed] [Google Scholar] 134.Chuang H.Y., Jeng W.Y., Wang E.H., Jiang S.T., Hsu C.M., Hsieh Y.M., Chio Y. Secreted Neutrophil Gelatinase-Associated Lipocalin Shows Stronger Ability to Inhibit Cr2 Enlargement of ADPKD Cells Compared with Nonsecreted Form. Cells. 2022;11:483. doi: 10.3390/cells11040483. [DOI] [PMC free article] [PubMed] [Google Scholar] 135.Malyszko J., Malyszko J.S., Koz-Zorawska E., Kozminski P., Mysliwiec M. Neutrophil gelatinase-associated lipocalin in dialyzed patients is related to residual renal function, type of renal replacement therapy and inflammation. Kidney Blood Press. Res. 2009;32:464-469. doi: 10.1159/000274048. [DOI] [PubMed] [Google Scholar] 136.Imanishi H., Ishii A., Yokoi H., Kasahara M., Kuwahara T., Mori K.P., Kato Y., Kuwahara T., Satoh M., Nakatani K., et al. Low Serum Neutrophil Gelatinase-associated Lipocalin Level as a Marker of Malnutrition in Maintenance Hemodialysis Patients. PLoS ONE. 2015;10:e0132539. doi: 10.1371/journal.pone.0132539. [DOI] [PMC free article] [PubMed] [Google Scholar] 137.Yazdani M., Merrikhi A., Beni Z.N., Baradaran A., Soleimani N., Musazade H. Association between neutrophil gelatinase-associated lipocalin and iron deficiency anemia in children on chronic dialysis. J. Res. Med. Sci. 2014;19:624-628. [PMC free article] [PubMed] [Google Scholar] 138.Aghsaefard Z., Alizadeh R., Bagheri N. Association between neutrophil gelatinase-associated lipocalin (NGAL) and iron profile in chronic renal disease. Arch. Physiol. Biochem. 2022;128:703-707. doi: 10.1080/13813455.2020.1720742. [DOI] [PubMed] [Google Scholar] 139.Jia X.Y., Wei K., Chen J., Xi L.H., Kong X.L., Wei Y., Wang L., Wang Z.S., Liu Y.P., Liang L.M., et al. Association of plasma neutrophil gelatinase-associated lipocalin with parameters of CKD-MBD in maintenance hemodialysis patients. J. Bone Miner. Metab. 2021;39:1058-1065. doi: 10.1007/s00074-021-0148-9. [DOI] [PubMed] [Google Scholar] 140.Yigit I.P., Ulu R., Gozel N., Tasakan H., Ilhan N., Dogukan A. Neutrophil gelatinase-associated lipocalin reflects the severity of anemia without cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study. J. Am. Coll. Cardiol. 2012;59:1101-1109. doi: 10.1016/j.jacc.2011.11.046. [DOI] [PMC free article] [PubMed] [Google Scholar] 141.Virz G.M., Mattiotti M., Manan M., Gnappi M., Tantillo L., Corrao G., Giuliani A., Garavito D., et al. Peritoneal NGAL: A reliable biomarker for PD-peritonitis monitoring. J. Nephrol. 2023;doi: 10.1007/s40602-022-01547-y. [DOI] [PubMed] [Google Scholar] 142.Martino F., Scalzoeto E., Giavarina D., Rodighiero M.P., Crepaldi C., Day S., Ronco C. The Role of NGAL in Peritoneal Dialysis Effluent in Early Diagnosis of Peritonitis: Case-Control Study in Peritoneal Dialysis Patients. Perit. Dial. Int. 2015;35:559-565. doi: 10.3747/pdi.2013.00300. [DOI] [PMC free article] [PubMed] [Google Scholar] 143.Lacquaniti A., Chirico V., Mondello S., Buemi A., Lupica R., Fazio M.R., Buemi M., Aloisi C. Neutrophil gelatinase-associated lipocalin in peritoneal dialysis reflects status of peritoneum. J. Nephrol. 2013;26:1151-1159. doi: 10.5301/jn.5000271. [DOI] [PubMed] [Google Scholar] 144.Choi H.M., Park K.T., Lee J.W., Cho E., Jo S.K., Cho W.Y., Kim H.K. Urine neutrophil gelatinase-associated lipocalin predicts graft outcome up to 1 year after kidney transplantation. Transplant. Proc. 2013;45:122-128. doi: 10.1016/j.transproc.2012.05.080. [DOI] [PubMed] [Google Scholar] 145.Yang J., Choi H.M., Seo M.Y., Lee J.Y., Kim K., Jun H., Jung C.W., Park K.T., Kim M.G., Jo S.K., et al. Urine liver-type fatty acid-binding protein predicts graft outcome up to 2 years after kidney transplantation. Transplant. Proc. 2014;46:376-380. doi: 10.1016/j.transproc.2013.11.130. [DOI] [PubMed] [Google Scholar] 146.Hollmen E., Kyllönen L.E., Inkinen K.A., Lalla M.L., Salmela T.J., Uusitalo P. Urine neutrophil gelatinase-associated lipocalin is a marker of graft recovery after kidney transplantation. Kidney Int. 2011;79:89-98. doi: 10.1038/kid.2010.351. [DOI] [PubMed] [Google Scholar] 147.Field M., Lowe D., Cobbold M., Higgins R., Briggs D., Inston N., Ready A.R. The use of NGAL and IP-10 in the prediction of early acute rejection in highly sensitized patients following HLA-incompatible renal transplantation. Transpl. Int. 2014;27:362-370. doi: 10.1111/tri.12266. [DOI] [PubMed] [Google Scholar] 148.Ramirez-Sandoval J.C., Herrington W., Morales-Buenrostro L.C. Neutrophil gelatinase-associated lipocalin in kidney transplantation: A review. Transplant. Rev. 2015;29:139-144. doi: 10.1016/j.trre.2015.04.004. [DOI] [PubMed] [Google Scholar] 149.Kim S.C., Payne E.K., Knechtel S.J. Urine proteomics in kidney transplantation. Transplant. Rev. 2014;28:15-20. doi: 10.1016/j.trre.2013.10.004. [DOI] [PubMed] [Google Scholar] 150.Devarajan P. Neutrophil gelatinase-associated lipocalin: A promising biomarker for human acute kidney injury. Biomark. Med. 2010;4:265-280. doi: 10.2217/bmm.10.12. [DOI] [PMC free article] [PubMed] [Google Scholar] [PubMed] [Google Scholar] 151.Ramirez-Sandoval J.C., Barrera-Chimal J., Simancas P.E., Correa-Rotter R., Bobadilla N.A., Morales-Buenrostro L.E. Tubular urinary biomarkers do not identify aetiology of acute kidney injury in kidney transplant recipients. Nephrology. 2014;19:352-358. doi: 10.1111/nap.12240. [DOI] [PubMed] [Google Scholar] 152.Cruz D.N., Gaio S., Maisel A., Ronco C., Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: A systematic review. Clin. Chem. Lab. Med. 2012;50:1533-1545. doi: 10.1515/ccclm.2012-0307. [DOI] [PMC free article] [PubMed] [Google Scholar] 153.Sivalingam Z., Larsen S.B., Grove E.L., Hvas A.M., Kristensen S.D., Magnusson E.N. Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease. Clin. Chem. Lab. Med. 2017;56:5-18. doi: 10.1515/ccclm.2017-0120. [DOI] [PubMed] [Google Scholar] 154.Yang H.H., Wang X., Li S., Liu Y., Akbar R., Fan G.C. Lipocalin family proteins and their diverse roles in cardiovascular disease. Pharmacol. Ther. 2023;244:108385. doi: 10.1016/j.pharmthera.2023.108385. [DOI] [PMC free article] [PubMed] [Google Scholar] 155.Helánová K., Pařenica J., Dlouhý V., Pávková Goldbergová M., Čermáková Z., Gottwaldová J., Spinar J. The importance of NGAL and cystatin C biomarkers in cardiovascular diseases. Vnitř. Lek. 2021;58:286-290. [PubMed] [Google Scholar] 156.Katagiri M., Takahashi M., Doi K., Myojo M., Kiyosue A., Ando J., Hirata Y., Komuro I. Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease. Heart Vessels. 2019;31:1595-1602. doi: 10.1007/s00380-015-0776-8. [DOI] [PubMed] [Google Scholar] 157.Daniels L.B., Barrett-Connor E., Clifton P., Laughlin G.A., Ix J.H., Maisel A.S. Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study. J. Am. Coll. Cardiol. 2012;59:1101-1109. doi: 10.1016/j.jacc.2011.11.046. [DOI] [PMC free article] [PubMed] [Google Scholar] 158.Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325. doi: 10.1038/nature10146. [DOI] [PubMed] [Google Scholar] 159.Van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombotic coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44. doi: 10.1161/01.CIR.89.1.36. [DOI] [PubMed] [Google Scholar] 160.Obero R., Bogalle E.P., Mathes L.A., Schuett H., Koch A.K., Grote K., Schieffer B., Schuett J., Luchtefeld M. Lipocalin (LCN 2) Mediates Pro-Atherosclerotic Processes and Is Elevated in Patients with Coronary Artery Disease. PLoS ONE. 2015;10:e0137924. doi: 10.1371/journal.pone.0137924. [DOI] [PMC free article] [PubMed] [Google Scholar] 161.Hemdal A.L., Gabrielsen A., Zhu C., Eriksson P., Hedin U., Kastrup J., Thorén P., Hansson G.K. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2006;26:136-142. doi: 10.1161/01.ATV.0000196376.88685.4. [DOI] [PubMed] [Google Scholar] 162.Lecleercq A., Houard X., Philippe M., Olivier V., Sebbag U., Meilhac O., Michel J.B. Involvement of intraplaque hemorrhage in atherothrombotic evolution via neutrophil protease enrichment. J. Leukoc. Biol. 2007;82:1420-1429. doi: 10.1189/ajb.1106671. [DOI] [PubMed] [Google Scholar] 163.Tee Boekhorst B.C., Bovens M.M., Hellings W.E., van der Kraak P.H., van de Kolk K.W., Vink A., Mol F.L., van Oosterhout M.F., de Vries J.P., Dooevensand P.A., et al. Molecular MRI of murine atherosclerotic plaque targeting NGAL: A protein associated with unstable human plaque characteristics. Cardiovasc. Res. 2011;89:680-688. doi: 10.1093/cvr/cvq340. [DOI] [PubMed] [Google Scholar] 164.Earl J., Kavanagh V., Stojkovic S., Kaider A., Kozakowski N., Domenig C.M., Burghuber C., Nanobachvili J., Huber K., Klingler M., Neumayer C., et al. NGAL and MMP-9/ALP as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis. Clin. Chem. Lab. Med. 2017;56:147-156. doi: 10.1515/ccclm-2017-0156. [DOI] [PubMed] [Google Scholar] 165.Kafkas N., Demponeri C., Zouboulou P., Spanou L., Babalis D., Makris K. Neutrophil gelatinase-associated lipocalin as an indicator of the inflammatory status in coronary artery disease. Int. J. Inflamm. 2012;2012:189797. doi: 10.1155/2012/189797. [DOI] [PMC free article] [PubMed] [Google Scholar] 166.Zografos T., Haliaouas A., Korovesis S., Giazitzoglou E., Vondis E., Katritsis D. Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease. Am. J. Cardiol. 2009;104:917-920. doi: 10.1016/j.amjcard.2009.05.023. [DOI] [PubMed] [Google Scholar] 167.Soylu K., Aksan G., Nar S., Özdemir M., Gülel O., İnci S., Aksakal A., Seyin A.L., Yılmaz Ö. Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome. Anatol. J. Cardiol. 2015;15:450-455. doi: 10.5152/ankd.2014.5513. [DOI] [PMC free article] [PubMed] [Google Scholar] 168.Sahinarslan A., Kocman S.A., Bas D., Akyel A., Ercil U., Zengin O., Timurkaynak T. Plasma neutrophil gelatinase-associated lipocalin levels in acute myocardial infarction and stable coronary artery disease. Coron. Artery Dis. 2011;22:333-338. doi: 10.1097/MCA.0b013e3283472a71. [DOI] [PubMed] [Google Scholar] 169.Li C., Zhang Z., Peng Y., Gao H., Wang Y., Zhao J., Pan C. Plasma neutrophil gelatinase-associated lipocalin levels are associated with the presence and severity of coronary heart disease. PLoS ONE. 2019;14:e0220841. doi: 10.1371/journal.pone.0220841. [DOI] [PMC free article] [PubMed] [Google Scholar] 170.Paulsson J., Daffar E., Held C., Jacobson S.H., Lundahl J. Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. Atherosclerosis. 2007;192:328-334. doi: 10.1016/j.atherosclerosis.2006.08.003. [DOI] [PubMed] [Google Scholar] 171.Chen Y., Fu Y., Wang S., Chen P., Pei Y., Zhang J., Zhang R., Niu G., Fu L. X. Clinical significance of neutrophil gelatinase-associated lipocalin and interleukin-6 in coronary artery disease in patients with type 2 diabetes mellitus aged ≥65 years. Cardiovasc. Diabetol. 2022;21:252. doi: 10.1186/s12933-0